ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last641 to 660 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to Cardiovascular Death269 of 6,992

257 of 6,978

0.2 points

-0.5 to 0.8

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Myocardial Infarction261 of 6,992

334 of 6,978

-1.1 points

-1.7 to -0.4

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to First Occurrence of Stroke135 of 6,992

158 of 6,978

-0.3 points

-0.8 to 0.1

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Three Component MACE575 of 6,992

663 of 6,978

-1.3 points

-2.2 to -0.3

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to All-cause Mortality434 of 6,992

420 of 6,978

0.2 points

-0.6 to 1.0

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)819 of 6,992

927 of 6,978

-1.6 points

-2.7 to -0.5

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to First Occurrence of Coronary Revascularization435 of 6,992

529 of 6,978

-1.4 points

-2.2 to -0.5

13,970NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: deaths from any cause437 of 7,001

420 of 6,964

0.2 points

-0.6 to 1.0

13,965NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Bempedoic Acid 180 mg vs Placebo Comparator: serious adverse events1,767 of 7,001

1,733 of 6,964

0.4 points

-1.1 to 1.8

13,965NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Phase I: Observational, Mother vs Phase I: Observational, Neonate: Post-discharge Readmission or Mortality231 of 7,060

349 of 6,891

-1.8 points

-2.5 to -1.1

13,951NCT05730387

Smart Discharges for Mom & Baby

Apixaban vs Warfarin: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital11,966 of 11,966

1,979 of 1,979

0.0 points

-0.0 to 0.2

13,945NCT05795062

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication57 of 6,950

84 of 6,950

-0.4 points

-0.7 to -0.1

13,900NCT01165229

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: Number of Subjects With Fatal Serious Adverse Events (SAEs)426 of 6,950

459 of 6,950

-0.5 points

-1.3 to 0.3

13,900NCT01165229

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: deaths from any cause426 of 6,950

459 of 6,950

-0.5 points

-1.3 to 0.3

13,900NCT01165229

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: serious adverse events1,153 of 6,950

1,214 of 6,950

-0.9 points

-2.1 to 0.4

13,900NCT01165229

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Ticagrelor 90 mg bd vs Clopidogrel 75 mg od: Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke751 of 6,930

740 of 6,955

0.2 points

-0.8 to 1.2

13,885NCT01732822

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Clopidogrel 75mg od vs Ticagrelor 90mg bd: serious adverse events1,788 of 6,932

1,716 of 6,910

1.0 points

-0.5 to 2.4

13,842NCT01732822

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events797 of 6,813

938 of 6,795

-2.1 points

-3.2 to -1.0

13,608NCT00097591

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke692 of 6,813

822 of 6,795

-1.9 points

-3.0 to -0.9

13,608NCT00097591

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had a Composite Primary Outcome675 of 6,767

702 of 6,756

-0.4 points

-1.4 to 0.6

13,523NCT02185417

Diuretic Comparison Project

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=33

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02993406-442f76e9",
        "title": "Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to Cardiovascular Death",
        "summary": "269 of 6992 against 257 of 6978; risk difference 0.2 points, 95% interval -0.5 to 0.8; NCT02993406, Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",
        "record": "/library/comparisons/NCT02993406-442f76e9",
        "nct_id": "NCT02993406",
        "kind": "outcome",
        "participants": 13970,
        "risk_difference": {
          "value": 0.0016425027858067154,
          "lower": -0.004686507646965966,
          "upper": 0.007976651855784203
        },
        "group_1": "269 of 6,992",
        "group_2": "257 of 6,978",
        "difference": "0.2 points",
        "interval": "-0.5 to 0.8",
        "trial_title": "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo"
      },
      {
        "id": "NCT02993406-72055ce6",
        "title": "Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Myocardial Infarction",
        "summary": "261 of 6992 against 334 of 6978; risk difference -1.1 points, 95% interval -1.7 to -0.4; NCT02993406, Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",
        "record": "/library/comparisons/NCT02993406-72055ce6",
        "nct_id": "NCT02993406",
        "kind": "outcome",
        "participants": 13970,
        "risk_difference": {
          "value": -0.010536342398109001,
          "lower": -0.017266398231678016,
          "upper": -0.0038411040442206876
        },
        "group_1": "261 of 6,992",
        "group_2": "334 of 6,978",
        "difference": "-1.1 points",
        "interval": "-1.7 to -0.4",
        "trial_title": "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=34",
  "request_id": "dt_a5sK3AHVIOyBd"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?